# Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.

> **NCT04239469** · PHASE2 · UNKNOWN · sponsor: **Knop Laboratorios** · enrollment: 44 (estimated)

## Conditions studied

- Fibromyalgia
- Cannabis

## Interventions

- **DRUG:** KL16-012
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04239469
- **Lead sponsor:** Knop Laboratorios
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2020-06-15
- **Final completion:** 2020-09-15
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239469, "Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04239469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*